Page 30 - Mylan EpiPen Teaching Note

PROBLEM: PRICING

Mylan’s revenue

increase was

aided when
Sanofi's

competing

product was

recalled in
November 2015

and further when

Teva's generic

competitor was
rejected by the

FDA in March

2016.

• Raised price of
EpiPen more than

400%

•Last six years

•A pack of two EpiPen’s $100 in 2009
•Today: $608

•17 price increases over period

•Mylan’s top-selling product ($1.5bn, 40% of profits)

•Not affordable for families
•No changes or updates to device